- recruitingPHASE2
Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection
This study is looking at a new medicine called tenofovir alafenamide (TAF) for children and teenagers aged 2-17 with long-term hepatitis B. It aims to see if TAF is safe and works better than a dummy medicine (placebo) and to find the right dose for different age groups.
United States · Belgium · Canada - enrolling by invitationPHASE1, PHASE2
TherVacB - A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate
This study is testing a new hepatitis B vaccine called TherVacB. It aims to see if it's safe and helps the body fight the hepatitis B virus in people who are already taking medication for it.
Germany - ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
TherVacB_Phase1a: Open phase 1a trial to assess the safety and immunogenicity of a heterologous protein prime/MVA boost therapeutic hepatitis B vaccine candidate in healthy volunteers
This study is testing a new vaccine for chronic hepatitis B. It's the very first time this vaccine will be given to people. Researchers want to see if it's safe and if it helps the body fight the hepatitis B virus.
Germany - recruitingNA
Fine Needle Aspiration (FNA) Evaluation of the Intrahepatic HBV Reservoir and Its Immunological Characteristics in Chronically HBV-infected Patients
This study aims to understand why hepatitis B (`hep B`) stays in the body, even with treatment. Researchers will use a small needle to take liver samples from people with `hep B`. This will help develop better treatments to cure the infection.
France - authorisedHuman Pharmacology (Phase I)- Other
A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-Human Study of Orally Administered DF-006 to Evaluate the Safety, Tolerability, and Pharmacokinetics After a Single Dose and Multiple Doses of Orally Administered DF-006 in Healthy Subjects (Part 1 and Part 2) and in Chronic Hepatitis B Patients (Part 3). Protocol Number Df-006-1001
This study is testing a new medicine, DF-006, for chronic hepatitis B. It looks at whether the medicine is safe, how the body handles it, and if it causes any side effects in healthy people and those with hepatitis B.
Romania · Bulgaria - ongoing, recruitingTherapeutic exploratory (Phase II)
Hepatitis B immunoglobulins to induce HBsAg clearance in patients with chronic hepatitis B (HBIG for cure)
This study is looking into a new way to treat long-term (chronic) hepatitis B. It uses special antibodies, called immunoglobulins, to help the body clear the hepatitis B virus. Researchers want to see if these antibodies can make the virus disappear from the blood after 12 weeks of treatment.
Germany - ongoing, recruitingTherapeutic exploratory (Phase II)
A phase II clinical trial to evaluate the safety, efficacy, and pharmacokinetics of RBD1016 injection in participants with chronic hepatitis B
This study is testing a new medicine, RBD1016, for chronic hepatitis B. We want to see how safe it is, how well it works to lower the virus, and how the body uses it. This is an early-stage study to gather important information.
Sweden - ongoing, recruitingTherapeutic exploratory (Phase II)
HepBTer: From fungus to virus, a phase 2a clinical trial investigating the safety and efficacy of terbinafine in chronic hepatitis B patients
This study, called HepBTer, is testing a medicine called terbinafine to see if it can help people with long-lasting hepatitis B. Researchers are looking at how safe the medicine is and if it reduces the amount of virus in the body over 10 weeks. This is an early-stage study.
Netherlands